VENIMMUN N

Powder and solvent for solution for infusion.
Active ingredient: modified human immunoglobulin (lVg)
Concentration: 50 mg/ml

Venimmun N contains mainly immunoglobulin G (lgG) with a broad spectrum of antibodies against infections agents.

Venimmun N is manufactured from plasma of at least 1000 donors. It has a distribution of immunoglobulin G subclasses closely proportional to that in native human plasma. Adequate doses of this medicinal product may restore low immunoglobulin G levels to the normal range. The mechanism of action in indications other than the replacement of anti-bodies (replacement therapy) is not fully elucidated, but includes influences on the immune reaction (immunomodulatory effects).

More than 20 years of broad clinical use

• Proven efficacy
• Long record of safety
• Product safety confirmed in controlled studies
• No confirmed cases of virus transfer
• Well-established tolerability.

HEMATOLOGY 

• Effective in autoimmune hemolysis
• Recommended as first-line in patients with severe post-transfusion purpura

NEUROLOGY

• In patients with multiple sclerosis (MS), lVlg has been used in investigational studies

RHEUMATOLOGY

• Used in severe RA
• Used in selected dermatomyositis patients

OBSTETRICS

• Used in reducing the incidence of first trimester abortion

ADULT HIV INFECTION

• Prophylactic lV immunoglobulin treatment in human immunodefiency virus-infected adults decreases the frequency of serious infections and is associated with a reduction of hospitalization for short-term care.